MedTrace Logo

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

NCT02472717 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-07-17

No results posted yet for this study

Summary

Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in patients with active Psoriatic Arthritis.

Conditions

Interventions

DRUG

liraglutide

Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks

OTHER

Placebo

Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02472717 on ClinicalTrials.gov